An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Adneuris Therapeutics, Inc.
Study ID
NCT07845071
Phase
PHASE3
Status
Recruiting

Conditions

  • Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Cebranopadol 400 ug — DRUG
    Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

Study Details

The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.

Key Dates

First listed
Sep 28, 2026
Start date
Sep 22, 2026
Status verified
Oct 2026
Primary completion
Jan 31, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
160 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cebranopadol
    Participants receive Cebranopadol 400 µg Starting dose 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

Primary Outcome Measure

Sum of pain intensity differences through 48 hours (SPID48) [ Time Frame: From 0 through 48 hours ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
Adneuris Site 001115PhoenixArizona85053-
Adneuris Site 001118RiversideCalifornia92504-
Adneuris Site 001119LongmontColorado80501-
Adneuris Site 001122SavannahGeorgia31406-
Adneuris Site 001123O'FallonIllinois62269-
Adneuris Site 001125AnnapolisMaryland21401-
Adneuris Site 001120OradellNew Jersey07649-
Adneuris Site 001124TulsaOklahoma74137-
Adneuris Site 001110BellaireTexas77401-
Adneuris Site 001117ForneyTexas75126-
Adneuris Site 001104McAllenTexas78501-
Adneuris Site 001116PlanoTexas75093-
Adneuris Site 001111San AntonioTexas78240-
Adneuris Site 001121San AntonioTexas78240-
Adneuris Site 001101Salt Lake CityUtah84107-

Find similar trials in Phoenix, AZ

Related Studies